EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Biological Evaluation of Evodiamine Derivatives as Antibody–Drug Conjugate Payloads

Ruifeng Liu, Yanfang Duan, Jing Jiang, Weihua Bian iD, Meiying Zhu iD

ChemMedChem · 2025

DOI: 10.1002/cmdc.202500268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Ruifeng Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Antibody-Drug Conjugate Innovation Group, Binzhou Medical University, Yantai, Shandong, 264003, China. Hauptthemen laut MEDLINE: Quinazolines, Drug Design, Antineoplastic Agents, Immunoconjugates. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, Shandong Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Natural product evodiamine derivatives exhibit multitarget bioactivities as dual topoisomerase (TOPO) I/II inhibitors, demonstrating remarkable potential in antitumor applications. Based on the evodiamine derivative D7‐03, six derivatives are synthesized. In vitro screening shows that D7‐09 has the strongest antitumor activity (IC 50 = 9.75–26.11 n m ) but poor hydrophobicity and solubility. D7‐03 with nM‐level cytotoxicity, better physicochemical properties, and high yield is chosen as the core payload for antibody‐drug conjugate (ADC) construction. The active molecule D7‐03 is further explored as an ADC payload by constructing four linker–toxin complexes. These complexes are conjugated with trastuzumab to generate ADC candidate molecules. Notably, Ab‐DL07‐D7‐03 exhibits superior activity (IC 50 = 8.369 and 4.899 n m in HCC1954 and NCI‐N87 cells, respectively) compared to the control group Ab‐LC08–SN38. This study is the first application of evodiamine derivatives as TOPO I/II dual inhibitors in the ADC field, which not only provides a new strategy for the development of ADC payloads, but also enriches the innovative application of natural product small molecules in tumor‐targeted therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinazolinesDrug DesignAntineoplastic AgentsImmunoconjugatesTopoisomerase I InhibitorsTopoisomerase II InhibitorsHumansDrug Screening Assays, AntitumorStructure-Activity RelationshipCell ProliferationCell Line, TumorMolecular StructureDose-Response Relationship, DrugDNA Topoisomerases, Type IDNA Topoisomerases, Type IICell Survival

Stichwörter der Autor:innen

antibody–drug conjugatesevodiaminepayloadstrastuzumab

Substanzen

evodiamineQuinazolinesAntineoplastic AgentsImmunoconjugatesTopoisomerase I InhibitorsDNA Topoisomerases, Type IDNA Topoisomerases, Type IITopoisomerase II Inhibitors

Autor:innen und Institutionen

  • Antibody-Drug Conjugate Innovation Group, Binzhou Medical University, Yantai, Shandong, 264003, China.

ORCID-Profile: Weihua Bian, Meiying Zhu

Förderung

  • Natural Science Foundation of Shandong Province
  • Shandong Provincial Natural Science Foundation

Zitieren

APA

Liu, R., Duan, Y., Jiang, J., Bian, W., & Zhu, M. (2025). Design, Synthesis, and Biological Evaluation of Evodiamine Derivatives as Antibody–Drug Conjugate Payloads. ChemMedChem. https://doi.org/10.1002/cmdc.202500268

Vancouver

Liu R, Duan Y, Jiang J, Bian W, Zhu M. Design, Synthesis, and Biological Evaluation of Evodiamine Derivatives as Antibody–Drug Conjugate Payloads. ChemMedChem. 2025. doi:10.1002/cmdc.202500268

BibTeX
@article{Liu2025,
  author = {Liu, Ruifeng and Duan, Yanfang and Jiang, Jing and Bian, Weihua and Zhu, Meiying},
  title = {Design, Synthesis, and Biological Evaluation of Evodiamine Derivatives as Antibody–Drug Conjugate Payloads},
  journal = {ChemMedChem},
  year = {2025},
  doi = {10.1002/cmdc.202500268}
}
Kostenlos starten →